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Numerous clinical clues suggest a possible
etiological relationship between serotonin,
"sclerosis" and connective tissue disorders.
Cutaneous sclerosis suggestive of scleroderma,
pulmonary fibrosis and endocardial fibrosis, for
example, have been reported occasionally in the
carcinoid syndrome (4, 9, 13). The endomyo-
cardial fibrosis seen in the "Matoke" (banana)
eating natives of East Africa has been attributed
to their elevated dietary typtophane which is a
serotonin precursor (1). Both they and the pa-
tients with the carcinoid syndrome have mark-
edly increased urinary 5-hydroxyindoleacetic
acid levels. Furthermore, patients with connec-
tive tissue disorders show an exaggerated re-
sponse to skin testing (7) and arterial infusion
(6) with serotonin. It has been suggested that
collagen diseases may be regarded as metabolic
diseases due to enzyme abnormalities, and indeed
disturbances in the metabolism of aromatic
amino-acids have been frequently reported (2, 5).
Because of these and other similar findings,
some investigators (8) are treating scleroderma
and other connective tissue disorders with various
serotonin antagonists. The purpose of the pres-
ent study was to measure the urinary 5-hydrox-
yindoleacetic acid excretion in patients with
systemic seleroderma.
MATERIAL AND METHODS
Ten patients with systemic seleroderma were
studied. There were nine females and one male.
The ages ranged from 18 to 56 years. The eases
chosen showed the clinical features of seleroderma
with far advanced changes. 5-hydroxy-3-indole-
acetic acid in 24-hour urine specimens was
measured by the eolorimetric method of Uden-
friend, Titus and Weissback (12).
RESULTS
The results obtained are listed on Table I.
The normal values for 24-hour urinary 5-hy-
droxyindoleacetic acid excretion range from 2.0
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to 9.0 mg. (3). It is noted that none of the values
were elevated.
DISCUSSION
There is insufficient evidence to allow more
than conjecture on the significance of serotonin
in seleroderma. No evidence for the inbreased
excretion of the serotonin metabolite, 5-hydroxy-
indoleacetie acid was found in this study. Other
metabolites which may have significance were
not studied.
TABLE I
5-Hydroxyindoleacetic acid excretion in .ecleroderma
Patient HIAA 24-Hour Urine
1 3.0 1350
2 3.8 840
3 2.3 2355
4 4.4 885
5 5.6 640
6 3.1 1260
7 7.2 810
S 4.3 960
9 6.8 1861
10 2.9 2100
Range 2.3—7.2 Normal 2.0—9.0
Mean 4.3
Standard Deviation 1.7
In a preceding paper (10) the inability to
reproduce cutaneous or systemic sclerosis with
massive doses of serotonin in hairless mice was
demonstrated. There is circumstantial evidence
implicating serotonin in the pathogenesis of
scleroderma, but direct proof is lacking. Sero-
tonin antagonists have wide-spread effects,
especially on the central nervous system. Though
the effects of therapy in seleroderma are most
difficult to evaluate (11), we have not yet been
impressed with clinical results obtained in selero-
derma with serotonin antagonists. Despite the
fact that there is little of therapeutic value
available to patients with seleroderma, the use of
these agents would seem of little benefit.
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SUMMARY
The 24-hour urinary excretion of the serotonin
metabolite 5-hydroxyindoleacetic acid in 10
patients with systemic seleroderma was normal.
This finding when added to experimental evi-
dence cited indicates that serotonin probably is
not a direct factor in the pathogenesis of selero-
derma. Treatment regimens based on antisero-
tonin activity would seem to have little ra-
tionality.
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